Matt Coffey, PhD

President and Chief Executive Officer, Chief Operating Officer

A co-founder of the Company, Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey has held the positions of Chief Operating Officer of the Company since December 2008, Chief Scientific Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004 and Chief Financial Officer from September 1999 to May 2000.


Kirk Look, CA

Chief Financial Officer

Mr. Look is a Chartered Accountant with more than fifteen years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company’s Controller in April 2003, and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst & Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst & Young LLP in Chile.


Andres A. Gutierrez, MD, PhD

Chief Medical Officer

Dr. Gutierrez is board certified in internal medicine and completed a fellowship in medical oncology. Most recently he has held progressively senior clinical development positions designing and implementing both early and later-stage oncology clinical studies at a range of U.S. and European companies including Sellas Life Sciences Group, Bristol-Myers Squibb, Sunesis Pharmaceuticals Inc., Biomarin Pharmaceutical Inc., Proteolix, and Oculus Innovative Sciences. Prior to that, he held a series of academic and consulting positions. Over his 32 year career, he has authored and co-authored more than 90 peer-reviewed publications and abstracts and presented at numerous conferences. He received his MD and a PhD in Biomedical Sciences from the National Autonomous University of Mexico.


George Gill, MD

Senior Vice President, Regulatory Affairs & Chief Safety Officer

George M. Gill, MD has more than thirty years of senior-level experience in Clinical Research and Regulatory Affairs, and has supported the advancement of more than twenty products – including eleven cancer products – through the regulatory approval process in the United States, Canada and Europe. Prior to joining Oncolytics, Dr. Gill held top positions with several major pharmaceutical companies including ICI Pharmaceuticals (now AstraZeneca), The Bristol-Myers Company (now Bristol-Myers Squibb) and Hoffman-La Roche. Dr. Gill holds a BSc in Chemistry from Dickinson College in Pennsylvania and an MD from the School of Medicine at the University of Pennsylvania. He is a Board Certified pediatrician and trained in hematology-oncology at the Children’s Hospital of Philadelphia (CHOP). He subsequently served on the staff at CHOP, Boston Children’s Hospital and then served as Chief of Hematology-Oncology at the Children’s Hospital of Newark, New Jersey.


Alan J Tuchman, MD, MBA (FAAN)

Chief Neuro-Oncology Officer

Dr. Tuchman is Clinical Professor of Neurology at New York Medical College and the author of over thirty scientific papers and book chapters. He is currently in the private practice of Neurology in Manhattan and consults to a number of biotechnology and investment firms. He has served as a partner of Xmark Opportunity Partners and as Executive Chairman of Neurophysics, Inc. He was previously the President of the Epilepsy Society of Southern New York as well as Vice Dean for Clinical Affairs at New York Medical College. Dr. Tuchman received his MD degree from the University of Cincinnati, College of Medicine, and completed his Neurology Residency at the Mt Sinai School of Medicine. Dr. Tuchman received his MBA from Columbia University.